Speeches & presentations

Search through our archive of speeches and presentations from conferences and events.

Filter by

  • Investor and Analyst call from ESMO 2019

    On Monday, 30 September 2019, Dr Hal Barron, Chief Scientific Officer and President R&D and Luke Miels, President, GSK Global Pharmaceuticals will host an investor conference call following the presentation of the PRIMA data on Zejula (niraparib) and the INDUCE-1 data on GSK’609 (ICOS) at the 2019 European Society for Medical Oncology (ESMO) congress. The call will also feature participation from an external expert in ovarian cancer and other GSK senior oncology leaders.

  • Roger Connor

    GSK Vaccines Investor Event

    Roger Connor, President, GSK Vaccines, hosted an educational session on GSK’s Vaccines business at our manufacturing site in Wavre, Belgium on Thursday 26 September at 13:30 CET / 12:30 BST / 7:30 EDT.

     

  • Dr Hal Barron, GSK

    Goldman Sachs’ 40th Annual Global Healthcare Conference, California

    Hal Barron, Chief Scientific Officer and President R&D, hosted a fireside chat at Goldman Sachs’ 40th Annual Global Healthcare Conference, which took place in Rancho Palos Verdes, California on Wednesday 12 June, during which he has provided an update on the progress being made in GSK’s R&D organisation.

  • David Redfern and Deborah Waterhouse

    Jefferies 2019 Healthcare Conference, New York

    David Redfern, Chief Strategy Officer of GSK and Chairman of ViiV Healthcare, and Deborah Waterhouse, CEO of ViiV Healthcare, hosted a fireside chat at the Jefferies 2019 Healthcare Conference in New York on Thursday 6 June, during which they provided an update on the progress GSK and ViiV Healthcare have made this year.

  • Tobias Hestler

    Bernstein Consumer Healthcare & Nutrition Seminar, London

    Tobias Hestler, CFO GSK Consumer Healthcare, hosted a fireside chat at the Bernstein Consumer Healthcare & Nutrition Seminar in London on Tuesday 4 June during which he provided an update on the Consumer Healthcare business and the formation of a new, world-leading Consumer Healthcare joint venture.

  • David Redfern and Deborah Waterhouse

    ViiV Healthcare analyst call

    David Redfern, Chairman ViiV Healthcare, Deborah Waterhouse, CEO ViiV Healthcare and Dr Kimberly Smith, VP Global Research & Medical Strategy hosted a ViiV Healthcare analyst call on Tuesday 30 April to discuss ViiV Healthcare’s recent regulatory activities and provide an update on the pipeline.

  • Luke Miels, President, Global Pharmaceuticals

    Cowen & Co. 39th Annual Health Care Conference, Boston

    Luke Miels, President Global Pharmaceuticals, hosted a fireside chat at the Cowen & Co. 39th Annual Health Care Conference 2019 in Boston on Tuesday 12 March, during which he provided an update on the progress GSK is making in the global pharmaceuticals and vaccines business.

  • Brian McNamara

    SVB Leerink Global Healthcare Conference, New York

    Brian McNamara, CEO GSK Consumer Healthcare, hosted a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference that took place in New York City on Thursday 28 February during which he provided an update on the Consumer Healthcare business and the formation of a new, world-leading Consumer Healthcare joint venture.

  • Guggenheim Healthcare Talks Idea Forum, New York

    Axel Hoos, SVP Oncology R&D, hosted a Fireside Chat at the Guggenheim Healthcare Talks Idea Forum - Oncology Day held in New York City on Thursday 14 February during which he provided an update on GSK Oncology R&D progress.

  • Emma Walmsley GSK CEO

    37th annual JP Morgan Healthcare Conference, San Francisco

    Emma Walmsley, CEO, gave a presentation at the 37th annual JP Morgan Healthcare Conference in San Francisco on Tuesday 8 January, providing an overview of GSK’s priorities and the progress the company made during 2018.

  • Analyst call on formation of new Consumer Healthcare JV

    On Wednesday 19 December 2018, GSK announced an agreement with Pfizer Inc to combine their consumer health businesses into a new world-leading Joint Venture. A call for investors and analysts was hosted by Emma Walmsley, Chief Executive Officer, Brian McNamara, CEO GSK Consumer Healthcare and Simon Dingemans, Chief Financial Officer.

  • David Redfern and Deborah Waterhouse

    ViiV Meet the Management, London

    David Redfern, Chairman ViiV Healthcare and Deborah Waterhouse, CEO ViiV Healthcare along with members of the ViiV Healthcare leadership team hosted a ViiV Healthcare Investor Event on Monday 10 December in London. The event included presentations from David, Deborah, Dr Kimberly Smith Global Research & Medical Strategy, Eric Dube Head of North America and Dr John Pottage Chief Scientific & Medical Officer and was followed by a Q&A session.

  • Dr Hal Barron, GSK

    Citi 2018 Global Healthcare Conference, New York

    Hal Barron, Chief Scientific Officer and President, R&D hosted a fireside chat at the Citi 2018 Global Healthcare Conference held in New York City on Wednesday 5 December, in which he provided an overview of GSK’s R&D priorities and progress made during 2018.

    Analyst webcast
  • Analyst call on agreement to acquire TESARO

    On Monday, 3 December 2018, GSK announced an agreement to acquire TESARO, an oncology-focused company based in the US. A call for investors and analysts was hosted by Emma Walmsley, Chief Executive Officer, Simon Dingemans, Chief Financial Officer, Dr Hal Barron, Chief Scientific Officer and President R&D, and Luke Miels, President, GSK Global Pharmaceuticals.

  • Evercore ISI HealthConX Conference, Boston

    Deborah Waterhouse, CEO, and Dr Kimberly Smith, Head of Global Research and Medical Strategy, ViiV Healthcare, hosted a fireside chat at the Evercore ISI HealthConX Conference held in Boston, Massachusetts on Wednesday 28 November, during which they provided an overview of ViiV’s priorities and progress made during 2018.

    Analyst webcast
  • Investor and Analyst call on GSK’165 aGM-CSF data presented at ACR

    On Tuesday, 23 October 2018, Dr Hal Barron, Chief Scientific Officer and President R&D and Luke Miels, President, GSK Global Pharmaceuticals hosted an investor conference call following the presentation of efficacy and safety data on GSK3196165, GSK's anti-GM-CSF antibody in development for Rheumatoid Arthritis at the 2018 American College of Rheumatology (ACR). The call also featured participation from an external expert in rheumatology and GSK’s Medicine Development Lead for GSK’165.

  • Brian McNamara

    Consumer Healthcare investor event, New Jersey

    Brian McNamara, CEO GSK Consumer Healthcare, and members of his leadership team hosted an investor event to review the Consumer Healthcare business. This event included a tour of our Shopper Science, Consumer Sensory and R&D labs, as well as presentations from Brian McNamara, Marc Speichert, SVP Digital and Richard Slater, SVP R&D, followed by a Q&A session.

  • Emma Walmsley GSK CEO

    CECP CEO Investor Forum

    Emma Walmsley, CEO, spoke at CECP’s CEO Investor Forum on Thursday 20 September 2018 about the steps we are taking to build trust – one of our three long-term priorities – and drive sustainable business performance.

    Watch the webcast on YouTube
  • Emma Walmsley GSK CEO

    Bank of America Merrill Lynch Global Healthcare Conference, London

    Emma Walmsley, CEO, gave a presentation at the Bank of America Merrill Lynch Global Healthcare Conference in London on Thursday 13 September 2018 in which she provided an overview of GSK’s priorities and progress made during 2018.

    Analyst webcast
  • David Redfern

    GEMINI Results of HIV 2 Drug Regimen Investor & Analyst Update

    On Tuesday, 24 July 2018, GSK hosted an investor conference call following the presentation of the full set of scientific and clinical data on GSK’s 2 drug regimen of dolutegravir plus lamiviudine (GEMINI studies) in treatment naïve HIV patients at the 22nd International AIDS Conference.

    The call was hosted by David Redfern, GSK Chief of Strategy and Chairman of ViiV Healthcare, Deborah Waterhouse, CEO of ViiV Healthcare, John Pottage, Chief Scientific & Medical Officer of ViiV Healthcare, and Kimberly Smith, VP Global Research & Medical Strategy of ViiV Healthcare.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5